[1] YURY G. KAMINSKY . Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25–35[J]. Experimental Neurology, 2010, 221 1: Pages 26-37. DOI:
10.1016/j.expneurol.2009.09.005[2] E. HUGHES A D R Burke. Inhibition of Toxicity in the Alzheimer’s Disease Peptide Fragment β(25–35) Using N-Methylated Derivatives[J]. Biochemical Society transactions, 2000, 28 1. DOI:
10.1042/bst028a072b[3] WEI G, JEWETT A I, SHEA J E. Structural diversity of dimers of the Alzheimer amyloid-β(25–35) peptide and polymorphism of the resulting fibrils†[J]. Physical Chemistry Chemical Physics, 2010, 14: 3622-3629. DOI:
10.1039/c000755m[4] YONG WANG . Mechanism of soluble beta-amyloid 25–35 neurotoxicity in primary cultured rat cortical neurons[J]. Neuroscience Letters, 2016, 618: Pages 72-76. DOI:
10.1016/j.neulet.2016.02.050[5] DOUGLAS K. RUSH Michael C M Suzann Aschmies. Intracerebral /sB-amyloid(25–35) produces tissue damage: Is it neurotoxic[J]. Neurobiology of Aging, 1992, 13 5: Pages 591-594. DOI:
10.1016/0197-4580(92)90061-2[6] HIROKO TSUNEKAWA . Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25–35)[J]. Behavioural Brain Research, 2008, 190 2: Pages 224-232. DOI:
10.1016/j.bbr.2008.03.002